Lupin’s arm launches AI-powered cardiometabolic wellness platform

30 Oct 2025 Evaluate

Lupin’s wholly owned subsidiary -- Lupin Digital Health has launched VITALYFE, an AI-powered cardiometabolic wellness platform designed to help India’s working professionals reclaim their heart health. Built on the foundation of LYFE - India’s first CDSCO-approved Class C software medical device (SaMD) for critical cardiac conditions - VITALYFE extends hospital-grade cardiac expertise to preventive wellness for its users.

Developed with industry-leading cardiometabolic expertise, VITALYFE uses artificial intelligence, behavioral science, and computer-vision technology to identify early risks and provide personalized, non-medical interventions that address the root causes of heart aging. Available exclusively through insurers, brokers, and employers, the platform enables organizations to integrate cardiometabolic wellness into their health benefits - improving productivity, engagement, and overall well-being while helping insurers reduce lifestyle-related claims.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2100.00 8.05 (0.38%)
05-Dec-2025 15:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.95
Dr. Reddys Lab 1274.35
Cipla 1520.95
Zydus Lifesciences 931.80
Lupin 2100.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×